The potential of sunitinib as a therapy in ovarian cancer

Umberto Leone Roberti Maggiore, Mario Valenzano Menada, Pier Luigi Venturini, Simone Ferrero

Research output: Contribution to journalArticlepeer-review


Introduction: Sunitinib malate (SU11248; Sutent®; Pfizer, Inc., New York) is a multi-kinase inhibitor currently approved for use in advanced renal cell carcinoma (RCC), imatinib-resistant/-intolerant gastrointestinal stromal tumours and progressive, well-differentiated pancreatic neuroendocrine tumours in patients with unresectable, locally advanced or metastatic disease. Areas covered: This article describes the mechanism of action and of the pharmacokinetics of sunitinib; further, it summarizes Phase I and II trials on the clinical efficacy, tolerability and safety of this agent in the setting of ovarian cancer (OC) treatment. Expert opinion: On the basis of the current literature, sunitinib has shown modest antitumour activity and acceptable toxicity. Studies investigating the impact of horizontal and vertical combinations should represent a priority of future research. Although clinical Phase II trials on the use of sunitinib in the treatment of OC demonstrated an acceptable profile of AEs, a greater comprehension of the toxicity of this compound is recommended.

Original languageEnglish
Pages (from-to)1671-1686
Number of pages16
JournalExpert Opinion on Investigational Drugs
Issue number12
Publication statusPublished - Dec 2013


  • Efficacy
  • Ovarian cancer
  • Safety
  • Sunitinib
  • Tolerability
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'The potential of sunitinib as a therapy in ovarian cancer'. Together they form a unique fingerprint.

Cite this